DPP4 in diabetes
D Röhrborn, N Wronkowitz, J Eckel - Frontiers in immunology, 2015 - frontiersin.org
Dipeptidyl-peptidase 4 (DPP4) is a glycoprotein of 110 kDa, which is ubiquitously expressed
on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal …
on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal …
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
S Shao, QQ Xu, X Yu, R Pan, Y Chen - Pharmacology & therapeutics, 2020 - Elsevier
Abstract Dipeptidyl peptidase 4 (DPP4) inhibitors (DPP4is) are oral anti-diabetic drugs
(OADs) for the treatment of type 2 diabetes mellitus (T2DM) through inhibiting the …
(OADs) for the treatment of type 2 diabetes mellitus (T2DM) through inhibiting the …
The growing incidence of bullous pemphigoid: overview and potential explanations
Bullous pemphigoid (BP) is the most common type of subepidermal autoimmune bullous
diseases. BP characteristically affects the elderly and is seen mainly in patients older than …
diseases. BP characteristically affects the elderly and is seen mainly in patients older than …
Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth
C Hollande, J Boussier, J Ziai, T Nozawa, V Bondet… - Nature …, 2019 - nature.com
Post-translational modification of chemokines mediated by the dipeptidyl peptidase DPP4
(CD26) has been shown to negatively regulate lymphocyte trafficking, and its inhibition …
(CD26) has been shown to negatively regulate lymphocyte trafficking, and its inhibition …
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
The success of antitumor immune responses depends on the infiltration of solid tumors by
effector T cells, a process guided by chemokines. Here we show that in vivo post …
effector T cells, a process guided by chemokines. Here we show that in vivo post …
Bullous pemphigoid: trigger and predisposing factors
Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal blistering disease
provoked by autoantibodies directed against two hemidesmosomal proteins: BP180 and …
provoked by autoantibodies directed against two hemidesmosomal proteins: BP180 and …
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
C Klemann, L Wagner, M Stephan… - Clinical & …, 2016 - academic.oup.com
Summary CD26/DPP4 (dipeptidyl peptidase 4/DP4/DPPIV) is a surface T cell activation
antigen and has been shown to have DPP4 enzymatic activity, cleaving-off amino-terminal …
antigen and has been shown to have DPP4 enzymatic activity, cleaving-off amino-terminal …
Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients
K Kridin, R Bergman - JAMA dermatology, 2018 - jamanetwork.com
Importance The association of bullous pemphigoid (BP) with the use of dipeptidyl-peptidase
4 (DPP-4) inhibitors among patients with diabetes has recently emerged. The risk of …
4 (DPP-4) inhibitors among patients with diabetes has recently emerged. The risk of …
Drug‐induced pemphigoid: a review of the literature
PG Stavropoulos, E Soura… - Journal of the European …, 2014 - Wiley Online Library
Bullous pemphigoid is an acquired autoimmune disease that is characterized by
subepidermal blistering and affects mainly the elderly. The pathogenesis of the condition …
subepidermal blistering and affects mainly the elderly. The pathogenesis of the condition …
[HTML][HTML] A systematic review of drug-associated bullous pemphigoid
MJ Verheyden, A Bilgic, DF Murrell - Acta dermato-venereologica, 2020 - ncbi.nlm.nih.gov
Bullous pemphigoid is an autoimmune subepithelial disease characterised by pruritus
followed by urticarial plaques and finally bullae on the skin and mucosa. Drug-associated …
followed by urticarial plaques and finally bullae on the skin and mucosa. Drug-associated …